Trial · NCT04253119
ART First-line Treatment Durability in Russia
NCT04253119, Completed, MSD Pharmaceuticals LLC; results first posted 2024-04-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. ART First-line Treatment Durability in Russia. Trials, record NCT04253119. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04253119
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- ART First-line Treatment Durability in Russia
- NCT number
- NCT04253119
- Status
- Completed
- Enrollment
- 536 participants, actual
- Lead sponsor
- MSD Pharmaceuticals LLC
- Conditions
- HIV-1-infection
- Interventions
- Antiretroviral/Anti HIV
- First posted
- 2020-02-05
- Last updated
- 2024-04-17
- Results first posted
- 2024-04-17
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 48 Weeks Treatment Durability | 48 weeks | Percentage of patients remained on initial therapy without change of the NNRTI or PI agent |
| Secondary | 96 Weeks Treatment Durability | 96 weeks | Percentage of patients remained on initial therapy without change of the NNRTI or PI agent |
| Secondary | Time on Therapy at 48 Weeks | 48 weeks | Estimated time on therapy without change of the NNRTI or PI agent at 48 weeks among treatment naive HIV-infected individuals initiated ART (NNRTI, PI) |
| Secondary | Time on Therapy at 96 Weeks | 96 weeks | Estimated time on therapy without change of the NNRTI or PI agent at 96 weeks among treatment naive HIV-infected individuals initiated ART (NNRTI, PI) |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | 48 Weeks Treatment Durability | 48 weeks | percentage of participants | NUMBER | |
| SECONDARY | 96 Weeks Treatment Durability | 96 weeks | percentage of participants | NUMBER | |
| SECONDARY | Time on Therapy at 48 Weeks | 48 weeks | weeks | MEAN | |
| SECONDARY | Time on Therapy at 96 Weeks | 96 weeks | weeks | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| 48 Weeks Treatment Durability | Treatment-naive at the Time of Initiation of ART Per the Usual Standard of Care. | 76.0 | 95% Confidence Interval 72.2 to 79.6 | percentage of participants | |
| 96 Weeks Treatment Durability | Treatment-naive at the Time of Initiation of ART Per the Usual Standard of Care. | 60.3 | 95% Confidence Interval 56.0 to 64.4 | percentage of participants | |
| Time on Therapy at 48 Weeks | Treatment-naive at the Time of Initiation of ART Per the Usual Standard of Care. | 46.8 | Standard Deviation 15.1 | weeks | |
| Time on Therapy at 96 Weeks | Treatment-naive at the Time of Initiation of ART Per the Usual Standard of Care. | 78.8 | Standard Deviation 33.8 | weeks |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment-naive at the Time of Initiation of ART Per the Usual Standard of Care. | 536 | |
| Overall Study | COMPLETED | Treatment-naive at the Time of Initiation of ART Per the Usual Standard of Care. | 536 | |
| Overall Study | NOT COMPLETED | Treatment-naive at the Time of Initiation of ART Per the Usual Standard of Care. | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment-naive at the Time of Initiation of ART Per the Usual Standard of Care. | 0 | 536 |
| Total, other adverse events | Treatment-naive at the Time of Initiation of ART Per the Usual Standard of Care. | 0 | 536 |
| Total, serious adverse events | Treatment-naive at the Time of Initiation of ART Per the Usual Standard of Care. | 0 | 536 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04253119
GET https://conductscience.org/api/trials/v1/NCT04253119/registered